Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients (scientific article published on 25 September 2018)

Concordance of hypervascular liver nodule characterization between the organ procurement and transplant network and liver imaging reporting and data system classifications

Q30867625

Classifying CT/MR findings in patients with suspicion of hepatocellular carcinoma: Comparison of liver imaging reporting and data system and criteria-free Likert scale reporting models

Q30977219

Liver Imaging Reporting and Data System:: Substantial Discordance Between CT and MR for Imaging Classification of Hepatic Nodules

Q31037369

Liver Imaging Reporting and Data System v2014 With Gadoxetate Disodium-Enhanced Magnetic Resonance Imaging: Validation of LI-RADS Category 4 and 5 Criteria

Q31046747

Liver imaging reporting and data system v2014 categorization of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: Comparison with multiphasic multidetector computed tomography

Q31118557

Liver Imaging Reporting and Data System: Review of Major Imaging Features

Q31136849

Liver Imaging Reporting and Data System: Review of Ancillary Imaging Features

Q31136851

Change in Liver Imaging Reporting and Data System Characterization of Focal Liver Lesions Using Gadoxetate Disodium Magnetic Resonance Imaging Compared With Contrast-Enhanced Computed Tomography

Q31140344

Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma

Q34558527

Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.

Q34585928

The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis

Q34614340

Repeatability of diagnostic features and scoring systems for hepatocellular carcinoma by using MR imaging.

Q34681046

Gadoxetic acid disodium-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: a meta-analysis

Q34963150

Imaging Techniques for the Diagnosis of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis

Q35634148

Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis.

Q35731141

Liver Imaging Reporting and Data System on CT and gadoxetic acid-enhanced MRI with diffusion-weighted imaging

Q36333396

Interreader and inter-test agreement in assessing treatment response following transarterial embolization for hepatocellular carcinoma

Q37143017

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

Q37696396

Hepatocellular carcinoma lesion characterization: single-institution clinical performance review of multiphase gadolinium-enhanced MR imaging--comparison to prior same-center results after MR systems improvements

Q37942142

Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models

Q37970349

Imaging-based diagnostic systems for hepatocellular carcinoma

Q38116045

Imaging surveillance and multidisciplinary review improves curative therapy access and survival in HCC patients.

Q38135695

Mammographic breast density: impact on breast cancer risk and implications for screening

Q38375009

Imaging for the Diagnosis of Hepatocellular Carcinoma: a Systematic Review and Meta-analysis

Q38599685

Differentiation of Hepatocellular Carcinoma from Other Hepatic Malignancies in Patients at Risk: Diagnostic Performance of the Liver Imaging Reporting and Data System Version 2014.

Q38602423

Hepatocellular carcinoma imaging systems: why they exist, how they have evolved, and how they differ.

Q38608806

LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents.

Q38614744

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

Q59150373

Magnetic resonance imaging with gadoxetic acid disodium for the detection of hepatocellular carcinoma: a meta-analysis of 18 studies

Q64125070

Liver transplantation for hepatocellular carcinoma without preoperative tumor biopsy

Q79690572

Factors related to shift from hepatic borderline lesion to overt HCC diagnosed by CT

Q86084278

Is liver-specific gadoxetic acid-enhanced magnetic resonance imaging a reliable tool for detection of hepatocellular carcinoma in patients with chronic liver disease?

Q87145592

Comparison of Visualization Rates of LI-RADS Version 2014 Major Features With IV Gadobenate Dimeglumine or Gadoxetate Disodium in Patients at Risk for Hepatocellular Carcinoma

Q88305386

Interobserver and intermodality agreement of standardized algorithms for non-invasive diagnosis of hepatocellular carcinoma in high-risk patients: CEUS-LI-RADS versus MRI-LI-RADS

Q88417197

Interobserver Agreement for Contrast-Enhanced Ultrasound (CEUS)-Based Standardized Algorithms for the Diagnosis of Hepatocellular Carcinoma in High-Risk Patients

Q89027131

CEUS LI-RADS: algorithm, implementation, and key differences from CT/MRI.

Q38618840

Liver Imaging Reporting and Data System: Discordance Between Computed Tomography and Gadoxetate-Enhanced Magnetic Resonance Imaging for Detection of Hepatocellular Carcinoma Major Features

Q38625869

How reader perception of capsule affects interpretation of washout in hypervascular liver nodules in patients at risk for hepatocellular carcinoma

Q38630810

Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm

Q38638574

Management implications and outcomes of LI-RADS-2, -3, -4, and -M category observations

Q38639541

Imaging features of hepatocellular carcinoma compared to intrahepatic cholangiocarcinoma and combined tumor on MRI using liver imaging and data system (LI-RADS) version 2014.

Q38647654

Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis

Q38667063

LI-RADS(®) algorithm: CT and MRI.

Q38684954

Diagnostic efficacy of the Liver Imaging-Reporting and Data System (LI-RADS) with CT imaging in categorising small nodules (10-20 mm) detected in the cirrhotic liver at screening ultrasound

Q38695722

Curative Resection of Single Primary Hepatic Malignancy: Liver Imaging Reporting and Data System Category LR-M Portends a Worse Prognosis.

Q38704974

Accuracy of the diagnostic evaluation of hepatocellular carcinoma with LI-RADS.

Q38710171

LI-RADS(®) ancillary features on CT and MRI.

Q38710312

Diagnostic Performance of Gadoxetic Acid-enhanced Liver MR Imaging versus Multidetector CT in the Detection of Dysplastic Nodules and Early Hepatocellular Carcinoma

Q38727935

Increased interreader agreement in diagnosis of hepatocellular carcinoma using an adapted LI-RADS algorithm.

Q39061895

Limitations of imaging diagnosis for small hepatocellular carcinoma: comparison with histological findings

Q39511294

Reliability, Validity, and Reader Acceptance of LI-RADS-An In-depth Analysis

Q39770545

Breast density: clinical implications and assessment methods

Q41238884

Critical analysis of the major and ancillary imaging features of LI-RADS on 127 proven HCCs evaluated with functional and morphological MRI: Lights and shadows

Q41612705

Rate of observation and inter-observer agreement for LI-RADS major features at CT and MRI in 184 pathology proven hepatocellular carcinomas.

Q41900119

Additional value of SPIO-enhanced MR imaging for the noninvasive imaging diagnosis of hepatocellular carcinoma in cirrhotic liver

Q43259464

LI-RADS technical requirements for CT, MRI, and contrast-enhanced ultrasound

Q43906532

LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma.

Q44796084

LI-RADS categories: concepts, definitions, and criteria.

Q45951332

Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma.

Q46022155

US LI-RADS: ultrasound liver imaging reporting and data system for screening and surveillance of hepatocellular carcinoma

Q46079816

Interreader Reliability of LI-RADS Version 2014 Algorithm and Imaging Features for Diagnosis of Hepatocellular Carcinoma: A Large International Multireader Study.

Q46141880

Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review.

Q46379419

Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI.

Q47326179

Extracellular contrast agent-enhanced MRI: 15-min delayed phase may improve the diagnostic performance for hepatocellular carcinoma in patients with chronic liver disease

Q47603110

LI-RADS: a glimpse into the future.

Q47741681

Comparison of the accuracy of AASLD and LI-RADS criteria for the non-invasive diagnosis of HCC smaller than 3 cm

Q49601264

Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants.

Q51275684

Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.

Q51541140

Value of delayed hypointensity and delayed enhancing rim in magnetic resonance imaging diagnosis of small hepatocellular carcinoma in the cirrhotic liver

Q51674471

LI-RADS for MR Imaging Diagnosis of Hepatocellular Carcinoma: Performance of Major and Ancillary Features.

Q52381627

LI-RADS 2017: An update.

Q52601515

Characterization of 1-to 2-cm liver nodules detected on hcc surveillance ultrasound according to the criteria of the American Association for the Study of Liver Disease: is quadriphasic CT necessary?

Q53100506

Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma.

Q53173190

Analysis of gadobenate dimeglumine-enhanced MR findings for characterizing small (1-2-cm) hepatic nodules in patients at high risk for hepatocellular carcinoma.

Q53435924

Triple-phase MDCT of hepatocellular carcinoma.

Q53631015

Intranodular Blood Supply Correlates Well with Biological Malignancy Grade Determined by Tumor Growth Rate in Pathologically Proven Hepatocellular Carcinoma

Q57763573

Non-invasive diagnosis of hepatocellular carcinoma ⩽2cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI

Q58021245

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

hepatocellular carcinoma

Q1148337

P304

page(s)

816-830

P577

publication date

2018-09-25

P1433

published in

Radiology

Q3285690

P1476

title

Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients

P478

volume

289

Reverse relations

cites work (P2860)

Q64084085	A scientometric analysis on hepatocellular carcinoma magnetic resonance imaging research from 2008 to 2017
Q92103963	Assessment of hepatocellular carcinoma treatment response with LI-RADS: a pictorial review
Q90513649	Characterization of liver nodules in patients with chronic liver disease by MRI: performance of the Liver Imaging Reporting and Data System (LI-RADS v.2018) scale and its comparison with the Likert scale
Q96817624	Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Q89959926	Comparison of Contrast-Enhanced Ultrasound versus Contrast-Enhanced Magnetic Resonance Imaging for the Diagnosis of Focal Liver Lesions Using the Liver Imaging Reporting and Data System
Q89623916	Controversies in the management of hepatocellular carcinoma
Q92694056	Detect or not to detect very early stage hepatocellular carcinoma? The western perspective
Q92747262	Development of an Ultrasound Prediction Model to Discriminate between Malignant and Benign Liver Lesions
Q96430846	Diagnostic Value of High Frame Rate Contrast-enhanced Ultrasonography and Post-processing Contrast Vector Imaging for Evaluation of Focal Liver Lesions: A Feasibility Study
Q92104112	HCC screening: assessment of an abbreviated non-contrast MRI protocol
Q89524883	Hepatocellular carcinoma demonstrates heterogeneous growth patterns in a multi-center cohort of patients with cirrhosis
Q61798324	Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
Q97543803	How to Best Detect Portal Vein Tumor Thrombosis in Patients with Hepatocellular Carcinoma Meeting the Milan Criteria: Gadoxetic Acid-Enhanced MRI versus Contrast-Enhanced CT
Q92108249	Intraindividual Comparison between Gadoxetate-Enhanced Magnetic Resonance Imaging and Dynamic Computed Tomography for Characterizing Focal Hepatic Lesions: A Multicenter, Multireader Study
Q89476435	LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features
Q98386350	Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis
Q89591808	Liquid biopsies for Hepatocellular cancer and their potential in clinical practice
Q90666212	Liver-specific 3D sectioning molds for correlating in vivo CT and MRI with tumor histopathology in woodchucks (Marmota monax)
Q91729664	Man or machine? Prospective comparison of the version 2018 EASL, LI-RADS criteria and a radiomics model to diagnose hepatocellular carcinoma
Q99583878	Quantitative analysis of multiphase magnetic resonance images may assist prediction of histopathological grade of small hepatocellular carcinoma
Q92073985	The Role of Preoperative Dynamic Contrast-enhanced 3.0-T MR Imaging in Predicting Early Recurrence in Patients With Early-Stage Hepatocellular Carcinomas After Curative Resection
Q93002175	Validated imaging biomarkers as decision-making tools in clinical trials and routine practice: current status and recommendations from the EIBALL* subcommittee of the European Society of Radiology (ESR)

P356	DOI	10.1148/RADIOL.2018181494
P932	PMC publication ID	6677371
P698	PubMed publication ID	30251931